| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
D. Boral Capital analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and maintains $12 price ...
A head-to-head study by Israel's Technion found that CollPlant's rhCollagen-based bioink, Collink.3D, outperformed Matr...
The bioprinted skin model is designed to serve as an alternative to animal testing for preclinical research.According to a scie...
CollPlant is now moving towards clinical trials and scaling and optimizing its manufacturing to ensure readiness for the upcomi...
D. Boral Capital analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and maintains $12 price ...
